Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Improvement in Patient-Reported SymptoMScreen Scores Among Ocrelizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis: 1-Year Results From the CASTING Clinical Trial
Multiple Sclerosis
P6 - Poster Session 6 (12:00 PM-1:00 PM)
9-009

SymptoMScreen is a patient-reported outcome designed to rapidly assess symptom limitations across 12 domains commonly affected by MS (walking, dexterity, spasticity, bodily pain, sensory, bladder function, fatigue, vision, vestibular, cognitive, depression and anxiety). Each domain is scored on 7-point Likert scale (0 [not affected] to 6 [total limitation]) and domain scores are summed to calculate a total score. SymptoMScreen is used in the ongoing, open-label, single-arm, Phase IIIb CASTING clinical trial.

To report 1-year changes in SymptoMScreen scores among patients with multiple sclerosis (MS) enrolled into the CASTING trial (NCT02861014).

In CASTING, patients with relapsing-remitting MS (Expanded Disability Status Scale [EDSS] score ≤4.0 at screening; disease duration ≤10 years), who had a suboptimal response to ≥1 disease-modifying therapy (DMT), receive ocrelizumab 600 mg/24 weeks intravenously for 96 weeks (first dose, 2×300 mg, 14 days apart). SymptoMScreen was performed at baseline and Week 48 (1-year interim data).

Patients (N=680; female, 64%; baseline EDSS [SD], 2.1 [1.1]); mean (SD) disease duration of 5.0 (2.7) years; 61% had received only one DMT prior to enrolment (most frequently, interferon-beta [29%]). At Week 48, SymptoMScreen total mean (SD) score significantly improved (p<0.001) from 15.19 (12.66) to 13.79 (11.95). Statistically significant improvements from baseline were observed for sensory symptoms (-0.31; p<0.001), vision (-0.23; p<0.001), fatigue (-0.21; p<0.001), dizziness (-0.14; p=0.004), cognition (-0.13; p=0.002), walking (-0.09; p=0.023), hand function (-0.08; p=0.037) and depression (-0.09; p=0.04) domains, while other domains showed improvements from baseline that did not reach statistical significance (p>0.05): spasticity (-0.02), bodily pain (-0.06), bladder control (-0.07) and anxiety (-0.01) domains.

Patients with MS and a suboptimal response to therapy who switched to ocrelizumab experienced symptomatic improvement after 1 year, which was most pronounced in sensory, fatigue and vision domains.

Authors/Disclosures
Ilya Kister, MD, FAAN (NYU School of Medicine)
PRESENTER
Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
Gary Raymond Cutter, PhD (University of Alabama At Birmingham) Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio, Medday, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, TG Therapeutics.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics, AI therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics,Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, NHLBI (Protocol Review Committee), University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc.. Dr. Cutter has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Regine Buffels, MD Dr. Buffels has nothing to disclose.
Susanne Clinch Susanne Clinch has received personal compensation for serving as an employee of Roche Products Limited. Susanne Clinch has stock in F.Hoffman-La Roche Ltd.
Wei Wei Wei Wei has received personal compensation for serving as an employee of Hoffmann -La Roche. Wei Wei has received stock or an ownership interest from Hoffmann-La Roche.
Patrick Vermersch (CHR de Lille) Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS-Celgene. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ad Scientiam. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Patrick Vermersch has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for La revue des microbiotes. The institution of Patrick Vermersch has received research support from Roche. The institution of Patrick Vermersch has received research support from Sanofi.